Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Failure Narrows Odds On Targacept Depression Drug; Hope Rests In Remaining Three Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

Nicotinic receptor company Targacept and TC-5214 partner AstraZeneca remain committed to a 2H 2012 filing of the drug as adjunct therapy for major depressive disorder.

Advertisement

Related Content

Targacept, AstraZeneca Face Another Failure With NNR Class
Targacept, AstraZeneca Face Another Failure With NNR Class
AstraZeneca Takes Impairment Charge After Olaparib, TC-5214 Setbacks
MDD Market Snapshot: Depressing Future For Antidepressants
AstraZeneca Drops Targacept's Failed ADHD Drug
AstraZeneca Pays $200M Upfront For Global Rights To Targacept's MDD Candidate

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073024

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel